Study Finds Infliximab Biosimilar Switch Is Safe, Effective for Patients with IBD
Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.
Source: hcplive.com
